On October 22, 2020 Targovax ASA (OSE:TRVX) ("Targovax" or the "Company"), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumor, on 14 October 2020, reported a successfully completed private placement of new shares in the Company (the "Private Placement") (Press release, Targovax, OCT 22, 2020, View Source [SID1234568792]).

The NOK 1,034,482.80 share capital increase pertaining to the Private Placement has now been registered with the Norwegian Register of Business Enterprises. The new share capital of the Company is NOK 8,652,059.20, divided into 86,520,592 shares, each with a par value of NOK 0.10.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new shares issued in the Private Placement will be listed on the Oslo Stock Exchange today.